Results from Kadcyla Phase III Trial, TH3RESA, and the impact this will have on the breast cancer market
Insight into BioMarin’s PARP inhibitor BMN-763 and it’s effectiveness for BRCA mutation-positive metastatic breast cancer patients
Find out the likelihood of trebananib/paclitaxel regimen being approved
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: